Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 263.83 CNY [4][10]. Core Views - The company reported a revenue of 36.726 billion CNY in 2024, representing a year-on-year growth of 5.14%, while the net profit attributable to shareholders was 11.668 billion CNY, a growth of 0.74% [1]. - The first quarter of 2025 showed a revenue of 8.237 billion CNY, a year-on-year decline of 12.12% but a quarter-on-quarter increase of 13.76% [1]. - The recovery in bidding activities since the end of 2024 is expected to gradually improve the company's performance [2]. - The company is positioned as a leader in industry digitalization, leveraging AI to enhance business expansion and innovate its business model [4][9]. Financial Performance Summary - In 2024, the company's revenue from life information and support business was 13.557 billion CNY, down 11.11% year-on-year, while the minimally invasive surgery segment grew over 30% [3]. - The in-vitro diagnostics business generated 13.765 billion CNY in 2024, marking a year-on-year increase of 10.82% [3]. - The medical imaging business achieved a revenue of 7.498 billion CNY in 2024, with international sales growing over 15% [3]. - The company expects revenue growth rates of 10.5%, 15.5%, and 14.6% for 2025 to 2027, respectively, with net profit growth rates of 9.7%, 15.3%, and 15.0% [10].

2025 年 05 月 05 日 生物医药Ⅱ 新药周观点：25Q1 创新药板块持仓环 比大幅提升 本周新药行情回顾： 2025 年 4 月 28 日-2025 年 5 月 2 日，新药板块涨幅前 5 企业：艾迪 药业（19.49%）、科伦博泰生物（17.02%）、乐普生物（16.09%）、 康诺亚（13.61%）、康宁杰瑞（13.60%）；跌幅前 5 企业：康方生物 （-11.22%）、宜明昂科（-10.03%）、东耀药业（-6.90%）、迈博药 业（-6.52%）、亚盛医药（-5.63%）。 本周新药行业重点分析： 根据最新披露的基金 2025 年第一季度报告，我们统计分析了全部所 有基金截止 2025 年 3 月 31 日对于创新药板块的最新重仓持仓情况 （注：在此仅统计了 A 股、港股 Biotech 创新药公司的基金重仓持 仓，对于以恒瑞医药为首的传统转型创新药企业未纳入统计；此外由 于基金季报仅披露重仓持仓情况，因此可能无法完全体现基金对创新 药板块的持仓情况）。 行业周报 证券研究报告 投资评级 领先大市-A 维持评级 | | | 行业表现 资料来源：Wind 资讯 升幅% 1M 3M 12M 相 ...

Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 263.83 CNY [4][10]. Core Views - The company reported a revenue of 36.726 billion CNY in 2024, a year-on-year increase of 5.14%, and a net profit of 11.668 billion CNY, up 0.74% year-on-year [1]. - The first quarter of 2025 showed a revenue of 8.237 billion CNY, a year-on-year decrease of 12.12%, but a quarter-on-quarter increase of 13.76% [1]. - The recovery in bidding activities since the end of 2024 is expected to gradually improve the company's performance [2]. - The company is positioned as a leader in industry digitization, leveraging AI to enhance business expansion and innovate its business model [4][9]. Financial Performance Summary - In 2024, the company's revenue from life information and support business was 13.557 billion CNY, a decrease of 11.11%, while the minimally invasive surgery segment grew over 30% [3]. - The in-vitro diagnostics business generated 13.765 billion CNY in 2024, marking a year-on-year growth of 10.82% [3]. - The medical imaging business achieved a revenue of 7.498 billion CNY in 2024, with a growth of 6.60% year-on-year [3]. - The company expects revenue growth rates of 10.5%, 15.5%, and 14.6% for 2025 to 2027, respectively, with net profit growth rates of 9.7%, 15.3%, and 15.0% [10].

2025 年 05 月 05 日 生物医药Ⅱ 新药周观点：25Q1 创新药板块持仓环 比大幅提升 本周新药行情回顾： 2025 年 4 月 28 日-2025 年 5 月 2 日，新药板块涨幅前 5 企业：艾迪 药业（19.49%）、科伦博泰生物（17.02%）、乐普生物（16.09%）、 康诺亚（13.61%）、康宁杰瑞（13.60%）；跌幅前 5 企业：康方生物 （-11.22%）、宜明昂科（-10.03%）、东耀药业（-6.90%）、迈博药 业（-6.52%）、亚盛医药（-5.63%）。 本周新药行业重点分析： 根据最新披露的基金 2025 年第一季度报告，我们统计分析了全部所 有基金截止 2025 年 3 月 31 日对于创新药板块的最新重仓持仓情况 （注：在此仅统计了 A 股、港股 Biotech 创新药公司的基金重仓持 仓，对于以恒瑞医药为首的传统转型创新药企业未纳入统计；此外由 于基金季报仅披露重仓持仓情况，因此可能无法完全体现基金对创新 药板块的持仓情况）。 行业周报 证券研究报告 投资评级 领先大市-A 维持评级 | | | 行业表现 资料来源：Wind 资讯 升幅% 1M 3M 12M 相 ...

Investment Rating - The report maintains a "Buy-A" rating for the company with a 12-month target price of 14.8 CNY per share [6][4]. Core Views - The company reported a Q1 2025 revenue of 5.037 billion CNY, a year-on-year decrease of 4.73%, but achieved a net profit attributable to shareholders of 104 million CNY, a significant increase of 447.56% year-on-year, primarily due to improved performance from Grammer [1][4]. - The company is expected to see accelerated growth in its passenger car seat business, driven by popular models such as L8, Lynk & Co 900, and Volkswagen Tayron, with projected seat revenues of 4.5 billion CNY in 2025 and 8.5 billion CNY in 2026 [2][4]. - The overseas integration efforts have shown positive results, with a significant improvement in North American operations and a streamlined European business following layoffs, indicating a return to normal operations for Grammer [3][4]. Financial Summary - The company forecasts net profits of 640 million CNY, 930 million CNY, and 1.18 billion CNY for 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 25, 17, and 13 [4][10]. - The projected revenue growth rates for the years 2025 to 2027 are 10.5%, 11.6%, and 10.3% respectively, indicating a robust growth trajectory [11]. - The company has a total market capitalization of approximately 15.67 billion CNY, with a current share price of 12.38 CNY [6][4].

Investment Rating - The investment rating for the company is "Buy-A" with a target price of HKD 135.84, which corresponds to a PE of 26x for 2025 [7]. Core Views - The company reported April delivery of 34,000 units, a year-on-year increase of 32% but a month-on-month decrease of 7%. The decline is attributed to the transition between old and new models, with the new MEGA Ultra version expected to boost sales [1][2]. - The upcoming launch of the L series smart refresh is anticipated to drive sales upward, with significant upgrades in technology and features [3]. - The company is positioned to enter a new product cycle with its pure electric series, supported by a robust charging infrastructure and positive market reception [4]. Summary by Sections Sales Performance - April sales showed a year-on-year increase of 32%, but a month-on-month decrease of 7%, influenced by the transition of models and ongoing promotions [1][2]. - The MEGA Ultra refresh and Home version are expected to enhance sales performance due to improved product features and marketing strategies [2]. Product Development - The L series smart refresh is set to launch in May, featuring significant technological upgrades that are likely to stimulate sales [3]. - The next-generation smart driving architecture, VLA model, is expected to enhance the company's competitive edge in the market [3]. Financial Projections - The company forecasts net profits of CNY 10.33 billion, CNY 16.03 billion, and CNY 17.74 billion for 2025, 2026, and 2027 respectively, with corresponding PE ratios of 18.9, 12.2, and 11.0 [11][13]. - The projected revenue growth rates for the upcoming years are 15.8% for 2025, 40.4% for 2026, and 20.0% for 2027, indicating a strong growth trajectory [13].

Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 32.79 CNY per share, compared to the current price of 22.58 CNY per share [4]. Core Views - The report indicates that the company has shown a recovery in sales, with April wholesale sales reaching 100,000 units, a year-on-year increase of 6% and a month-on-month increase of 2% [2]. - The introduction of new models, such as the Tank 300 and the second-generation Haval Max, is expected to contribute positively to sales growth [2][3]. - The company is entering a new growth phase, with expectations of increased sales in the mainstream market and significant potential in the off-road vehicle segment [3]. Sales Performance - April sales included 29,000 units of new energy vehicles, a year-on-year increase of 28% and a month-on-month increase of 14%, while fuel vehicle sales were 71,000 units, showing a year-on-year decrease of 2% [2]. - The Tank brand sold 19,000 units in April, with the Tank 300 contributing significantly to this figure, achieving sales of 11,000 units, a year-on-year increase of 13% [2]. - Haval brand sales reached 57,000 units in April, a year-on-year increase of 21%, attributed to the launch of the second-generation Haval Max [2]. Financial Forecast - The company is projected to achieve net profits of 140.3 billion CNY, 174.0 billion CNY, and 209.6 billion CNY for the years 2025, 2026, and 2027 respectively, with corresponding price-to-earnings ratios of 13.8, 11.1, and 9.2 [8][9]. - Revenue is expected to grow from 1,732.1 billion CNY in 2023 to 3,364.9 billion CNY by 2027, indicating a strong growth trajectory [9][10]. Market Outlook - The report suggests that the mainstream market for new vehicles is entering a growth phase, with the company’s refined product offerings and marketing strategies likely to drive sales upward [3]. - The Hi4Z technology is expected to enhance the company's competitive edge in the off-road vehicle market, potentially leading to significant profit margins [3]. - The company has a diverse product lineup and strong technological capabilities, which are anticipated to boost export potential as new models are introduced [3].

Investment Rating - The investment rating for BYD is "Buy-A" with a target price of 454.25 CNY per share, maintaining the rating [6]. Core Views - The report highlights that BYD's April sales performance was robust, with a total of 371,000 passenger vehicles sold, representing a year-on-year increase of 19% and a month-on-month stability. Pure electric vehicle sales reached 196,000 units, up 46% year-on-year and 18% month-on-month [1]. - The report emphasizes the strong performance of high-end brands, with sales of the Tengshi brand increasing by 38% year-on-year and 22% month-on-month, driven by the launch of the Tengshi N9 [2]. - The overseas sales of BYD's new energy vehicles reached 79,000 units in April, marking a 93% year-on-year increase and a 9% month-on-month increase, attributed to new model launches and enhanced logistics capabilities [3]. - The outlook for BYD is positive, with expectations for continued growth in core operations, high-end product offerings, and international expansion [4]. Summary by Sections Sales Performance - In April, BYD sold 371,000 passenger vehicles, with pure electric sales at 196,000 units and plug-in hybrid sales at 177,000 units. The sales figures indicate a year-on-year growth driven by new models, while month-on-month performance remained stable [1]. High-End Brand Growth - The Tengshi brand saw sales of 15,000 units in April, a 38% increase year-on-year, while the Fangchengbao brand experienced a remarkable 376% year-on-year growth, primarily due to the launch of the Titanium 3 model [2]. International Expansion - BYD's overseas sales reached 79,000 units in April, with significant growth in various regions, including the Asia-Pacific, Americas, Europe, and Africa. The company is also expanding its production capacity with a new factory in Cambodia [3]. Future Outlook - The report anticipates that BYD will continue to enhance its competitive edge through increased product intelligence and high-end offerings. The company is expected to maintain strong growth in exports, benefiting from higher pricing and profitability in international markets [4].

Group 1 - The report indicates that the A-share market is transitioning into a "volatile market" mindset, with strong expectations but weak realities, without significant risk of a second bottom [2][3] - A key positive factor is the easing of the US-China tariff conflict, which is expected to enhance risk-on sentiment in the A-share market post-holiday [2][3] - The report highlights that the domestic economic fundamentals are resilient but show signs of weakening, with industrial profits in Q1 2025 growing by 0.8% year-on-year, reversing a decline from the previous year [3][4] Group 2 - The report emphasizes the "second wave of technology" in the market, suggesting that the technology sector is poised for recovery, particularly in AI and semiconductor industries [4][5] - The technology sector's trading volume has decreased to 32.55%, indicating a reduction in trading congestion, which may lead to a rebound in this sector [4][5] - The report suggests that high-dividend stocks and technology should be part of a barbell strategy for investment, with a focus on the semiconductor and smart driving sectors as key areas of growth [4][5] Group 3 - The report notes that the A-share market has completed the earnings disclosures for 2024 annual reports and Q1 2025 reports, with a year-on-year profit growth of 1.32% for Q1 2025 [61][64] - It highlights that the overall A-share profitability remains at a low level, with significant variations in profit growth across different sectors, particularly in upstream and midstream industries [64][66] - The report identifies that the electronics sector has maintained high growth, while traditional consumer sectors are experiencing a decline in growth rates [64][66]

Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 26.01 CNY, compared to the current stock price of 20.87 CNY [7]. Core Views - The company's performance in Q1 2025 showed a decline in operating income by 3.58% year-on-year, with a decrease in pre-provision profit by 4.35% and net profit attributable to shareholders down by 2.22%. The main factors affecting performance were the expansion of interest-earning assets and a decline in net non-interest income [2][10]. - The asset quality remains stable, with a non-performing loan ratio of 1.08% and a provision coverage ratio of 233.42% as of Q1 2025, indicating a reasonable level of asset quality management [10][11]. Summary by Sections Financial Performance - In Q1 2025, the company's total assets grew by 3.65% year-on-year, with total loans increasing by 4.83%. The bank added 123.4 billion CNY in total assets and 78.8 billion CNY in loans during the quarter [3][4]. - The net interest margin for Q1 2025 was 1.80%, showing a year-on-year decline of 7 basis points, while the cost of liabilities decreased, helping to mitigate the impact of declining interest margins [6][10]. Loan and Deposit Structure - Corporate loans showed a year-on-year growth of 6.33%, with a focus on supporting the real economy, particularly in green and technology loans, which exceeded 1 trillion CNY [4][5]. - Retail loan growth was weak, with a year-on-year increase of only 0.96%, and a net decrease of 26 billion CNY in retail loans during the quarter [4]. Non-Interest Income and Cost Management - Non-interest income declined by 12.42% year-on-year, primarily due to a 21.50% drop in investment income, although net fee income increased by 8.54% [10][11]. - The cost-to-income ratio increased slightly to 24.13%, reflecting the impact of declining income [11]. Future Outlook - The company is expected to maintain stable credit issuance while enhancing deposit cost control, with an anticipated decline in net interest margin of around 10 basis points for the year [11]. - Revenue is projected to grow by 0.54% year-on-year in 2025, with net profit growth estimated at 1.91% [11].